Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition

European Journal of Clinical Pharmacology

Volumn 55, Issue 6, 1999, Pages 461-467

  Rouru, J ^a   Gordin, A ^b   Huupponen, R ^a   Huhtala, S ^a   Savontaus, E ^a   Korpela, K ^b   Reinikainen, K ^b   Scheinin, M ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b Espoo Research Centre   (Finland)

Author keywords

Entacapone; Levodopa; Pharmacokinetics

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG SCREENING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DRUG INTERACTIONS; ENZYME INHIBITORS; ERYTHROCYTES; HUMANS; LEVODOPA; MALE;

EID: 0032785423     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050657     Document Type: Article

References (19)

1. Ahtila S, Kaakkola S, Gordin A, Korpela K, Heinävaara S, Karlsson M, Wikberg T, Tuomainen P, Männistö PT (1995) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 18: 46-57
2. Assal F, Spahr L, Hadengue L, Rubbicci-Brandt L, Burkhart PR (1998) Tolcapone and fulminant hepatitis. Lancet 352: 958
3. Bonifati V, Meco G (1998) New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease. Pharmacol Ther 81: 1-36
4. Heikkinen H, Pentikäinen PJ, Saraheimo M, Ahtila S, Ottoila P (1994) Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: a study using stable isotope technique (abstract). Proceedings of 11th International Symposium on Parkinson's Disease, Rome, Italy, 26-30 March, p 301
5. Kaakkola S, Gordin A, Männistö PT (1994a) General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 25: 813-824
6. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994b) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77-80
7. Karlsson M, Wikberg T (1992) Liquid Chromatographic determination of a new catechol-O-methyl-transferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J Pharmacol Biomed Anal 10: 593-600
8. Keränen T, Gordin A, Harjola V-P, Kalsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145-156
9. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L, Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
10. McNeely W, Davis R (1997) Entacapone. CNS Drugs 8: 79-88
11. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913-919
12. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42: 747-755
13. Rinne UK, Larsen JP, Siden Å, Worm-Petersen J and the Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51: 1309-1314
14. Ruottinen H, Rinne UK (1996a) Effect of one month's treatment with peripherally acting COMT inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19: 222-233
15. Ruottinen HM, Rinne UK (1996b) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advances Parkinson's disease. Clin Neuropharmacol 19: 283-296
16. Ruottinen HM, Rinne UK (1996c) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60: 36-40
17. Ruottinen HM, Rinne UK (1998) COMT inhibition in the treatment of Parkinson's disease. J Neurol 245[Suppl 3]:25-34
18. Schultz E, Nissinen E, Kaakkola S (1989) Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection. Biomed Chromatogr 3: 64-67
19. Wikberg T (1991) Simultaneous determinations of levodopa, its main metabolites and carbidopa in plasma by liquid chromatography. J Pharmacol Biomed Anal 9: 167-176